● Recruiting

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

Condition: Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma · Sponsor: North Eastern German Society of Gynaecological Oncology

PhasePhase 2

Planned participants640

Who can joinFemale, 18 Years to no upper limit

Healthy volunteersNo

About this study

Multicenter, randomized, open label study including patients with advanced HRDpositive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary with no residual tumor mass following primary tumor debulking to determine recurrence free survival in patients treated with 3 cycles carboplatin + paclitaxel and maintenance therapy with niraparib vs. 6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib.

This description comes directly from the study's public registry record.

Talk to the study team

Jessica Nguyen · 4930403686539 · jessica.nguyen@noggo.de

Jasmin Yamamoto · 4930403686532 · jasmin.yamamoto@noggo.de

Always discuss trial participation with your own doctor first.

Locations (50)

Universitätsklinik Innsbruck	Innsbruck, Austria	Recruiting
Cliniques Universitaires St. Luc	Brussels, Belgium	Active Not Recruiting
UZ Gent	Ghent, Belgium	Active Not Recruiting
Jessa ziekenhuis	Hasselt, Belgium	Recruiting
UZ Leuven	Leuven, Belgium	Active Not Recruiting
University Hospital Ostrava	Ostrava, Czechia	Recruiting
General University Hospital in Prague	Prague, Czechia	Recruiting
University Hospital Bulovka	Prague, Czechia	Active Not Recruiting
Universitätsklinikum Aachen	Aachen, Germany	Recruiting
Klinikum Mittelbaden Baden-Baden Bühl	Baden-Baden, Germany	Not Yet Recruiting
DRK-Kliniken Berlin-Köpenick	Berlin, Germany	Recruiting
Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum	Berlin, Germany	Recruiting

+ 38 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05460000